FDA Approves Taletrectinib for ROS1-positive Non-Small Cell Lung Cancer By Ogkologos - July 4, 2025 644 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the TRUST-I and TRUST-II studies Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Lurbinectedin Zongertinib Shows Durable Antitumour Activity in First-Line Treatment for Patients with Previously Untreated HER2-mutated Advanced NSCLC Patient Guide on Immunotherapy Side Effects and Their Management Now Available Also in the Ukrainian MOST POPULAR Life beyond cancer: Improving the long term side effects for children... September 22, 2022 Inseparable Couples Dies 33 Hours Apart After 68 Years Of Marriage:... December 5, 2019 Adding Pembrolizumab to Platinum-Based Chemotherapy Improves Survival in Patients with Previously... June 23, 2023 Η ΚΑΘΗΜΕΡΙΝΟΤΗΤΑ December 10, 2018 Load more HOT NEWS Νέος βιοδείκτης για τις γυναίκες πριν την εμμηνόπαυση Synchronized Swimmer Learns She Has Breast Cancer After Teammate Kicks Her... How the National Cancer Act Has Made a Difference in Cancer... Long-Term Outcomes from the CheckMate 067 Study in Patients With Advanced...
